Advances in Breast Cancer Treatment

ASCO SIGN IN

Manage Email Subscriptions

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

ASCO Membership Directory

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Press Center

Advances in Breast Cancer Treatment

EMBARGOED FOR RELEASE
UNTIL EARLIER OF: START OF PRESS BRIEFING OR START OF SCIENTIFIC SESSION

See attached summaries for exact times

CONTACT:
Annual Meeting News Room
312-949-3200

ASCO Media Information Line
212-584-5010

-- PRESS BRIEFING SATURDAY, MAY 31, 9:00 AM CDT --

-- Anti-Bone-Loss Drug Reduces Recurrence Risk in Early Breast Cancer Patients; Bevacizumab with Docetaxel Slows Cancer Growth in Patients Newly Diagnosed with Advanced Breast Cancer --

Chicago, IL— Plenary and late-breaking studies that advance the treatment of both early and advanced breast cancer were released today at a press briefing at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).

“We have a multitude of therapies for women with breast cancer, but continue to need new treatments that are more effective and have fewer side effects,” said Eric Winer, MD, professor of medicine at Harvard Medical School, director of the Breast Oncology Center at Dana-Farber Cancer Institute and moderator of the press briefing. “Our goal is to prevent recurrence and prolong survival for patients with early-stage breast cancer, and control disease and improve survival for patients with advanced disease.”

Study findings include:

A plenary study found that giving zoledronic acid (Zometa), a drug used to treat bone metastases and recently approved to treat osteoporosis, to premenopausal women undergoing ovarian suppression and hormone therapy significantly reduces the risk of recurrence in early-stage breast cancer.
A late-breaking study found that adding bevacizumab (Avastin) to docetaxel (Taxotere) slows disease progression for patients newly diagnosed with locally advanced or metastatic breast cancer. This study adds to previous findings on bevacizumab for treating breast cancer.

The press briefing also highlighted research on the effectiveness of chemotherapy after surgery for older women with early-stage breast cancer. The study suggests that standard adjuvant chemotherapy is effective in older women and cannot be replaced by the entirely oral chemotherapy agent, capecitabine. The study is important since little data exist on the effects of adjuvant chemotherapy in older women, and physicians have little guidance about whether chemotherapy may do more harm than good in this population. VIEW SUMMARY

For consumer-oriented information on these studies and more than 120 cancer types and cancer-related syndromes, please refer your readers to ASCO’s oncologist-vetted patient website, www.cancer.net.

VIEW FULL PRESS RELEASE